Tigecycline
Tetracyclines
Sold as TYGACIL
- Drug class
- Tetracyclines
- Availability
- See label
- Routes
- Intravenous
- Markets covered
- 3
- Products on record
- 16
Overview
Tigecycline is an active pharmaceutical ingredient in the Tetracyclines group (J01AA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 11 | May 1, 2026 |
| CA Canada | Health Canada | 3 | December 5, 2025 |
| EU European Union | EMA | 2 | October 22, 2025 |
GBUnited Kingdom· MHRA
11 products
Uses
4); • Complicated intra-abdominal infections (cIAI). 1). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
How to take
CACanada· Health Canada
3 products
Uses
TIGECYCLINE (tigecycline) is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms in patients 18 years of age and older: • Complicated skin and skin structure infections (cSSSI) caused by Escherichia coli, Enterococcus faecalis (vancomycin-susceptible strains only), Staphylococcus aureus (methicillin-susceptible and-resistant strains), Streptococcus agalactiae, Streptococcus anginosus, Streptococcus pyogenes, Enterobacter cloacae, Klebsiella pneumoniae, and Bacteroides fragilis.
Patients with severe underlying disease, such as those who were immunocompromised, patients with decubitus ulcer infections, or patients who had infections requiring longer than 14 days of treatment (for example, necrotizing fasciitis), were not enrolled in clinical trials.
• Complicated intra-abdominal infections (cIAI) caused by Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Enterococcus faecalis (vancomycin-susceptible strains only), Staphylococcus aureus (methicillin-susceptible only), Streptococcus anginosus grp.
EUEuropean Union· EMA
2 products
Uses
4); • Complicated intra-abdominal infections (cIAI). 1). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
How to take
Drug interactions
Known interactions involving Tigecycline. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL363900442 · revised May 1, 2026
- [2]Health Canada (DPD) · 02409356 · revised March 22, 2025
- [3]European Medicines Agency · EMEA/H/C/000644 · revised October 22, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.